<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892824</url>
  </required_header>
  <id_info>
    <org_study_id>CL-326</org_study_id>
    <nct_id>NCT03892824</nct_id>
  </id_info>
  <brief_title>Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants</brief_title>
  <acronym>CAPTURE2</acronym>
  <official_title>Carotid Artery ImPlant for Trapping UpstReam Emboli (CAPTURE 2) for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Javelin Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety of the Vine™ Embolic Protection System (embolic filtering
      device) in atrial fibrillation (AF) patients on top of oral anticoagulants (OAC), and remain
      at high risk for stroke recurrence. All patients will receive bilateral implants in the
      common carotid arteries
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Vine™ filter (Vine™ or implant) is a permanent carotid filter designed for stroke
      prevention in AF patients taking OAC at high stroke risk (CHA2DS2-VASc ≤ 4 and stroke
      history). This patient population accounts for ~20% of the entire AF population, which is
      ~300K/year in the United State and EU. The implant is designed to exclude emboli &gt; 1.2mm in
      size from reaching the anterior circulation. In AF patients, approximately 80% of strokes are
      total or partial anterior circulation strokes caused by occlusions of the main branches of
      the Circle of Willis, mainly M1-2, and rarely A1-2. The diameter of these branches, in the
      majority of cases, is &gt; 1.5 mm
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or implantation procedure complications</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>Major Adverse Events (MAEs) within 30 days of the final index (implantation) procedure, defined as the composite that includes any of the following:
Any ischemic stroke with ischemic foci confined to the territories of Vine™ implanted arteries
Hemorrhagic stroke or major hemorrhage while receiving additional antithrombotic therapy required for Vine™ implantation
Any Vine™ or Vine™ implantation procedure-related complication that requires surgery or endovascular treatment, or results in death or major disability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or Device complications.</measure>
    <time_frame>one year from implantation procedure</time_frame>
    <description>Any ischemic stroke with ischemic foci confined to the territories of Vine™ implanted arteries
Hemorrhagic stroke or major hemorrhage while receiving additional antithrombotic therapy required for Vine™ implantation
Any Vine™ or Vine™ implantation procedure-related complication that requires surgery or endovascular treatment, or results in death or major disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of properly positioned implants</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>proper implant position in each common carotid artery (CCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that had disabling strokes</measure>
    <time_frame>30 days and one year from implantation procedure</time_frame>
    <description>Disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Implantation success</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>implantation attempt resulting in proper implant position immediately after the procedure without any device/procedure related complication that requires surgery or endovascular treatment for correction, or that results in death or major disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of properly positioned implants</measure>
    <time_frame>one year from implantation procedure</time_frame>
    <description>Proper implant position in each CCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of observed thrombi on the device</measure>
    <time_frame>30 days and one year from implantation procedure</time_frame>
    <description>Thrombus on implant detected by ultrasound imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death cases</measure>
    <time_frame>one year from implantation procedure</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of strokes (any kind)</measure>
    <time_frame>one year from implantation procedure</time_frame>
    <description>Total number of strokes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Vine™ Filter + OAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vine™ Embolic Protection System</intervention_name>
    <description>The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (&quot;Needle Unit&quot;) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled &quot;Loaded Needle Unit&quot;) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button.</description>
    <arm_group_label>Vine™ Filter + OAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented AF

          -  CHA2DS2-VASc score ≥ 4 and history of ischemic stroke (including TIA with positive
             neuro-imaging)

          -  No contra-indication for patient to receive an OAC, either vitamin K antagonist (VKA)
             or novel oral anticoagulant (NOAC) for the duration of the study

          -  Age &gt; 50 years

          -  Maximal (systolic) CCA diameter range: ≥ 4.8mm and ≤ 9.8mm

          -  CCA accessibility: up to 40mm from skin to CCA center, safe approach

          -  Implantation segment free of atherosclerotic disease as determined by ultrasound
             imaging

          -  Patient is able and willing to provide informed consent

        Exclusion Criteria:

          -  Evidence of carotid stenosis &gt; 30% [CCA, internal carotid artery (ICA), or external
             carotid artery (ECA)]

          -  Evidence of carotid dissection

          -  Pre-existing stent(s) in CCA

          -  Female who is pregnant or who is planning to become pregnant during the course of the
             study

          -  Life expectancy of less than one year

          -  Active systemic infection

          -  Known sensitivity to nickel or titanium metals, or their alloys

          -  Known hereditary or acquired coagulation disorders

          -  Any planned surgical or endovascular treatment within 30 days after the implantation
             procedure

          -  A co-morbid disease or condition that could confound the neurological and functional
             evaluations or compromise survival or ability to complete follow-up assessments*
             Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as
             regular or daily consumption of more than four alcoholic drinks per day)

          -  Active participation in another investigational drug or device treatment study

          -  Inability to complete all scheduled follow-up

          -  Any other condition that in the opinion of the investigator may adversely affect the
             safety of the patient or would limit the patient's ability to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sagit Broder, M.Sc</last_name>
    <phone>972-4-7701267</phone>
    <phone_ext>206</phone_ext>
    <email>sagit@javelinmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>maria Berson, B.Sc</last_name>
    <phone>972-4-7701270</phone>
    <phone_ext>209</phone_ext>
    <email>Maria@javelinmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom De Potter, M.D</last_name>
      <email>tom.de.potter@olvz-aalst.be</email>
    </contact>
    <contact_backup>
      <last_name>Hedwig Batjoens</last_name>
      <email>Hedwig.Batjoens@OLVZ-aalst.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye, M.D</last_name>
      <email>stefan.verheye@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, M.D.</last_name>
      <email>Petr.Neuzil@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Petr Moucka</last_name>
      <email>Petr.Moucka@homolka.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Alfried-Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Veltkamp, M.D</last_name>
      <email>roland.veltkamp@krupp-krankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardio Vasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horst Sievert, M.D</last_name>
      <email>horst@sievert.md</email>
    </contact>
    <contact_backup>
      <last_name>Sabine deBruijn</last_name>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Schmidt, M.D</last_name>
      <email>b.schmidt@ccb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Hippokrateio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Konstantinos Toutouzas, M.D</last_name>
      <email>ktoutouz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Interbalkan Medical Center</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Apostolos Tzikas, M.D</last_name>
      <email>aptzikas@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geza Fontos, M.D</last_name>
      <email>geza.fontos@kardio.hu</email>
    </contact>
    <contact_backup>
      <last_name>Orsolya Nagy</last_name>
      <email>zs.nagyorsi@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Soroka</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Motti Haim, M.D</last_name>
      <email>MotiH@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carmel</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ofer Galili, M.D</last_name>
      <email>offerga@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Ariela Goldberg</last_name>
      <email>arielago1@clslit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shaari Tzedek</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaron Almagor, M.D</last_name>
      <email>almagor@szmc.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Michel Glikson</last_name>
      <email>mglikson@szmc.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Poria</name>
      <address>
        <city>Tiberias</city>
        <zip>1520800</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahim Marai, M.D</last_name>
      <email>imarai@poria.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Jana Etkin</last_name>
      <email>JEtkin@poria.health.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Masjuan, M.D</last_name>
      <email>jaime.masjuan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF</keyword>
  <keyword>Stroke</keyword>
  <keyword>Filter</keyword>
  <keyword>Emboli</keyword>
  <keyword>Carotid</keyword>
  <keyword>OAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

